Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).

Kristina A ColeSharmistha PalRachel A KudgusHeba IjazXiaowei LiuCharles G MinardBruce R PawelJohn M MarisDaphne A Haas-KoganStephan D VossStacey L BergJoel M ReidElizabeth FoxBrenda J Weigel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Adavosertib (85 mg/m2) in combination with irinotecan (90 mg/m2) administered orally for 5 days was the MTD in children and adolescents with solid and CNS tumors.

Keyphrases

clinical trial
acute lymphoblastic leukemia
acute myeloid leukemia
young adults
diffuse large b cell lymphoma
multiple myeloma
hodgkin lymphoma
blood brain barrier
phase ii
open label
double blind
randomized controlled trial
phase iii